JP2013505017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505017A5 JP2013505017A5 JP2012529714A JP2012529714A JP2013505017A5 JP 2013505017 A5 JP2013505017 A5 JP 2013505017A5 JP 2012529714 A JP2012529714 A JP 2012529714A JP 2012529714 A JP2012529714 A JP 2012529714A JP 2013505017 A5 JP2013505017 A5 JP 2013505017A5
- Authority
- JP
- Japan
- Prior art keywords
- dna construct
- cells
- cell
- vibrio cholerae
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 108020004414 DNA Proteins 0.000 claims description 30
- 241000602423 Vibrio cholerae O1 Species 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 229960005486 vaccine Drugs 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 241000209094 Oryza Species 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- 108020004511 Recombinant DNA Proteins 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000004873 anchoring Methods 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 206010008631 Cholera Diseases 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 231100000033 toxigenic Toxicity 0.000 claims description 3
- 230000001551 toxigenic effect Effects 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27235109P | 2009-09-16 | 2009-09-16 | |
| US61/272,351 | 2009-09-16 | ||
| PCT/SE2010/050996 WO2011034495A1 (en) | 2009-09-16 | 2010-09-16 | Vaccine against cholera and enterotoxigenic e. coli (etec) diarrhea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015227296A Division JP6178384B2 (ja) | 2009-09-16 | 2015-11-20 | コレラおよび毒素原性大腸菌（ｅｔｅｃ）下痢に対するワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505017A JP2013505017A (ja) | 2013-02-14 |
| JP2013505017A5 true JP2013505017A5 (enExample) | 2013-07-04 |
Family
ID=43758898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529714A Pending JP2013505017A (ja) | 2009-09-16 | 2010-09-16 | コレラおよび毒素原性大腸菌（ｅｔｅｃ）下痢に対するワクチン |
| JP2015227296A Active JP6178384B2 (ja) | 2009-09-16 | 2015-11-20 | コレラおよび毒素原性大腸菌（ｅｔｅｃ）下痢に対するワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015227296A Active JP6178384B2 (ja) | 2009-09-16 | 2015-11-20 | コレラおよび毒素原性大腸菌（ｅｔｅｃ）下痢に対するワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9511133B2 (enExample) |
| EP (1) | EP2477649B1 (enExample) |
| JP (2) | JP2013505017A (enExample) |
| KR (1) | KR101722802B1 (enExample) |
| CN (1) | CN102630166B (enExample) |
| AU (1) | AU2010296065B2 (enExample) |
| CA (1) | CA2774335C (enExample) |
| DK (1) | DK2477649T3 (enExample) |
| ES (1) | ES2616912T3 (enExample) |
| HU (1) | HUE031957T2 (enExample) |
| IN (1) | IN2012DN02860A (enExample) |
| PL (1) | PL2477649T3 (enExample) |
| PT (1) | PT2477649T (enExample) |
| WO (1) | WO2011034495A1 (enExample) |
| ZA (1) | ZA201202710B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| CN102824632A (zh) * | 2012-09-12 | 2012-12-19 | 北京民海生物科技有限公司 | 霍乱弧菌o1群多糖结合疫苗、其制备方法及应用 |
| RU2535122C1 (ru) * | 2013-11-06 | 2014-12-10 | Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") | Способ получения холерогена-анатоксина |
| RU2563620C2 (ru) * | 2014-08-05 | 2015-09-20 | Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") | Способ получения таблетированной формы холерной бивалентной химической вакцины |
| CN108431230B (zh) * | 2015-12-14 | 2023-02-21 | 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 | 用于产生经纯化重组霍乱毒素B(rCTB)的新方法及其制剂 |
| EP3450556B1 (en) * | 2016-04-27 | 2022-03-23 | Osaka University | Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same |
| WO2019115001A1 (en) | 2017-12-15 | 2019-06-20 | Valneva Sweden Ab | Methods and compositions for preventing and/or treating cancer |
| WO2021005623A1 (en) * | 2019-07-08 | 2021-01-14 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera |
| WO2021105061A1 (en) | 2019-11-25 | 2021-06-03 | Gotovax Ab | Whole cell vaccines and methods of production thereof |
| EP4058056A1 (en) | 2020-10-07 | 2022-09-21 | Valneva Sweden AB | Cholera vaccine formulation |
| WO2022117823A1 (en) * | 2020-12-04 | 2022-06-09 | Valneva Se | Methods and compositions for preventing and/or treating autoimmune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882653A (en) * | 1983-03-04 | 1999-03-16 | The University Of Maryland System | Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof |
| US5330753A (en) * | 1987-04-29 | 1994-07-19 | President And Fellows Of Harvard College | Cholera vaccines |
| JP4179627B2 (ja) * | 1992-07-06 | 2008-11-12 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | コレラワクチンとしての欠失変異体 |
| US6203799B1 (en) * | 1993-07-01 | 2001-03-20 | Presidents And Fellows Of Harvard College | Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit |
| JP3098401B2 (ja) | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
| AU4994600A (en) * | 1999-05-10 | 2000-11-21 | University Of Maryland At Baltimore | Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof |
| US7270961B2 (en) * | 2002-04-16 | 2007-09-18 | Hui Sunny Chang | In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes |
| US20060171966A1 (en) * | 2002-08-30 | 2006-08-03 | Centre For Health And Population Research | Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype |
| CU23334A1 (es) * | 2003-03-20 | 2008-12-24 | Inst Finlay | Vacuna de vibrio cholerae inactivada en tabletas |
| US20060099229A1 (en) * | 2004-11-05 | 2006-05-11 | Universiti Sains Malaysia | Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof |
| EP1543836A1 (en) * | 2003-12-17 | 2005-06-22 | Berna Biotech AG | Recombinant Vibrio cholerae strain and vaccine comprising said strain |
| US8642046B2 (en) * | 2007-10-09 | 2014-02-04 | Tufts University | Cholera vaccines |
-
2010
- 2010-09-16 CN CN201080041458.1A patent/CN102630166B/zh active Active
- 2010-09-16 WO PCT/SE2010/050996 patent/WO2011034495A1/en not_active Ceased
- 2010-09-16 US US13/496,183 patent/US9511133B2/en active Active
- 2010-09-16 AU AU2010296065A patent/AU2010296065B2/en active Active
- 2010-09-16 HU HUE10817520A patent/HUE031957T2/en unknown
- 2010-09-16 ES ES10817520.9T patent/ES2616912T3/es active Active
- 2010-09-16 EP EP10817520.9A patent/EP2477649B1/en active Active
- 2010-09-16 PT PT108175209T patent/PT2477649T/pt unknown
- 2010-09-16 IN IN2860DEN2012 patent/IN2012DN02860A/en unknown
- 2010-09-16 KR KR1020127009647A patent/KR101722802B1/ko not_active Expired - Fee Related
- 2010-09-16 PL PL10817520T patent/PL2477649T3/pl unknown
- 2010-09-16 DK DK10817520.9T patent/DK2477649T3/en active
- 2010-09-16 JP JP2012529714A patent/JP2013505017A/ja active Pending
- 2010-09-16 CA CA2774335A patent/CA2774335C/en active Active
-
2012
- 2012-04-13 ZA ZA2012/02710A patent/ZA201202710B/en unknown
-
2015
- 2015-11-20 JP JP2015227296A patent/JP6178384B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505017A5 (enExample) | ||
| US12403335B2 (en) | Betacoronavirus MRNA vaccines | |
| US20230114180A1 (en) | Respiratory syncytial virus vaccine | |
| JP7330590B2 (ja) | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン | |
| US20220202934A1 (en) | Respiratory virus nucleic acid vaccines | |
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| JP2010516290A5 (enExample) | ||
| US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
| JP2008529558A5 (enExample) | ||
| CN106061995A (zh) | Uspa2蛋白质构建体及其用途 | |
| CN111601605A (zh) | 用于施用rna的制剂 | |
| AU2015292261B2 (en) | Constrained proteins and uses therefor | |
| JP7046014B2 (ja) | 伝染性喉頭気管炎ウイルスおよび伝染性ファブリキウス嚢病ウイルスの抗原をコードする組換え非病原性マレック病ウイルスコンストラクト | |
| TW202108598A (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| WO2023023940A1 (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| CN103627718B (zh) | 表达ibv s1和n双抗原蛋白重组质粒及其构建方法和应用 | |
| Wan et al. | As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity-and IL-6-dependent manner | |
| WO2024209218A1 (en) | Coronavirus vaccines inducing broad immunity against variants | |
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| Basirnejad et al. | Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant | |
| CN111172177B (zh) | cra4S1基因及其编码的蛋白和应用 | |
| US20250277007A1 (en) | Cwp2 protein as an effective vaccine against clostridioides difficile infection | |
| Fatemi et al. | Vaccine Development and Immune Responses in COVID-19: Lessons from the Past | |
| Quintana‐Vázquez et al. | A vaccination strategy consisting of Semliki‐Forest‐virus (SFV) DNA prime and fowlpox‐virus boost significantly protects mice from a recombinant (HIV‐1) vaccinia‐virus infection |